113 related articles for article (PubMed ID: 7906583)
1. In vitro cytotoxic activity of Taxol and Taxotere on primary cultures and established cell lines of human ovarian cancer.
Silvestrini R; Zaffaroni N; Orlandi L; Oriana S
Stem Cells; 1993 Nov; 11(6):528-35. PubMed ID: 7906583
[TBL] [Abstract][Full Text] [Related]
2. Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines.
Kelland LR; Abel G
Cancer Chemother Pharmacol; 1992; 30(6):444-50. PubMed ID: 1356649
[TBL] [Abstract][Full Text] [Related]
3. In vitro antiproliferative activity of docetaxel (Taxotere), paclitaxel (Taxol) and cisplatin against human tumour and normal bone marrow cells.
Braakhuis BJ; Hill BT; Dietel M; Kelland LR; Aapro MS; Zoli W; Lelieveld P
Anticancer Res; 1994; 14(1A):205-8. PubMed ID: 7909419
[TBL] [Abstract][Full Text] [Related]
4. Comparative studies of taxol and taxotere on tumor growth and lymphocyte functions.
Munkarah A; Chuang L; Lotzová E; Cook K; Morris M; Wharton JT
Gynecol Oncol; 1994 Nov; 55(2):211-6. PubMed ID: 7959286
[TBL] [Abstract][Full Text] [Related]
5. Electrochemical monitoring of anticancer compounds on the human ovarian carcinoma cell line A2780 and its adriamycin- and Cisplatin-resistant variants.
Woolley DE; Tetlow LC; Adlam DJ; Gearey D; Eden RD; Ward TH; Allen TD
Exp Cell Res; 2002 Feb; 273(1):65-72. PubMed ID: 11795947
[TBL] [Abstract][Full Text] [Related]
6. Abrogation of taxol-induced G2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids.
Frankel A; Buckman R; Kerbel RS
Cancer Res; 1997 Jun; 57(12):2388-93. PubMed ID: 9192815
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of taxol and taxotere in comparison with doxorubicin and cisplatin on primary cell cultures of human breast cancers.
Zoli W; Flamigni A; Frassineti GL; Bajorko P; De Paola F; Milandri C; Amadori D; Gasperi-Campani A
Breast Cancer Res Treat; 1995 Apr; 34(1):63-9. PubMed ID: 7749161
[TBL] [Abstract][Full Text] [Related]
8. Taxane sensitivity of ovarian carcinoma in vitro.
Engblom P; Rantanen V; Kulmala J; Heiskanen J; Grenman S
Anticancer Res; 1997; 17(4A):2475-9. PubMed ID: 9252666
[TBL] [Abstract][Full Text] [Related]
9. Taxol and taxotere in bladder cancer: in vitro activity and urine stability.
Rangel C; Niell H; Miller A; Cox C
Cancer Chemother Pharmacol; 1994; 33(6):460-4. PubMed ID: 7907952
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
11. In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin.
Jensen PB; Holm B; Sorensen M; Christensen IJ; Sehested M
Br J Cancer; 1997; 75(6):869-77. PubMed ID: 9062409
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol.
Yu D; Liu B; Jing T; Sun D; Price JE; Singletary SE; Ibrahim N; Hortobagyi GN; Hung MC
Oncogene; 1998 Apr; 16(16):2087-94. PubMed ID: 9572489
[TBL] [Abstract][Full Text] [Related]
13. Taxotere inhibits in-vitro growth of human colonic cancer cell lines.
Karantanis E; Nicholson S; Morris DL
Eur J Surg Oncol; 1994 Dec; 20(6):653-7. PubMed ID: 7995417
[TBL] [Abstract][Full Text] [Related]
14. Effects of Taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells.
Hanauske AR; Degen D; Hilsenbeck SG; Bissery MC; Von Hoff DD
Anticancer Drugs; 1992 Apr; 3(2):121-4. PubMed ID: 1356030
[TBL] [Abstract][Full Text] [Related]
15. Treatment with paclitaxel alone rather than combination with paclitaxel and cisplatin may be selective for cisplatin-resistant ovarian carcinoma.
Yamamoto K; Kikuchi Y; Kudoh K; Hirata J; Kita T; Nagata I
Jpn J Clin Oncol; 2000 Oct; 30(10):446-9. PubMed ID: 11185891
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of taxotere (RP 56976, NSC 628503), a new taxol analog, in experimental ovarian cancer.
Boven E; Venema-Gaberscek E; Erkelens CA; Bissery MC; Pinedo HM
Ann Oncol; 1993 Apr; 4(4):321-4. PubMed ID: 8100146
[TBL] [Abstract][Full Text] [Related]
17. Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients.
Sonnemann J; Gänge J; Pilz S; Stötzer C; Ohlinger R; Belau A; Lorenz G; Beck JF
BMC Cancer; 2006 Jul; 6():183. PubMed ID: 16834771
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (Taxotere): association with impaired repositioning of the microtubule organizing center.
Hotchkiss KA; Ashton AW; Mahmood R; Russell RG; Sparano JA; Schwartz EL
Mol Cancer Ther; 2002 Nov; 1(13):1191-200. PubMed ID: 12479700
[TBL] [Abstract][Full Text] [Related]
19. Interaction of ionizing radiation with paclitaxel (Taxol) and docetaxel (Taxotere) in HeLa and SQ20B cells.
Hennequin C; Giocanti N; Favaudon V
Cancer Res; 1996 Apr; 56(8):1842-50. PubMed ID: 8620502
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel and docetaxel in breast and ovarian cancer.
Drug Ther Bull; 1997 Jun; 35(6):43-6. PubMed ID: 9282422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
